Sleep Disorders in Multiple Sclerosis: Present-Day Knowledge and Future Perspectives

Keywords: Multiple sclerosis; Sleep; Fatigue; Mood; Demyelination; Psychiatric manifestations

Introduction

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system characterized by demyelination and axonal loss. It usually occurs in individuals aged between 20 and 40 years and constitutes the first cause of non-traumatic disability in young adults. Through the disease course, patients may suffer from a plethora of symptoms including sensory, motor, cerebellar complaints, but also fatigue, cognitive deficits, psychiatric manifestations and sleep disturbances. Fatigue could be a very debilitating and difficult-to-treat symptom with a prevalence reaching up to 90% [1,2]. Psychiatric comorbidities, namely anxiety and depression, might occur in up to 95% of patients and could even herald MS diagnosis [3]. Cognitive deficits can affect about 65% of patients [4,5]. Importantly, sleep disturbances are commonly reported by MS patients where they could occur approximately four times more than in the general population [1,6]. Sleep disturbances could be either due to co-morbid sleep disorders or secondary to several factors that frequently happen in MS. To start, regarding comorbid sleep disorders, the occurrence of restless leg syndrome has been found to be 5.4 times greater in MS patients compared to the general public and seems to arise from hypothalamic and cervical spine lesions [1]. Sleep apnea is another condition that may be related to brainstem lesions or medication-induced hypotonia of pharyngeal muscles [1]. Rapid eye movement behavior disorders could also arise in MS patients and seem to be linked to dorsal pontine lesions [1]. Other encountered sleep syndromes include periodic limb movements and narcolepsy-cataplexy [1]. Furthermore, the restorative sleep capacity may be altered in this population as a consequence to functional and pathological changes of the disease itself, such changes would lead to excessive daytime sleepiness [1]. It is worth noting that, in a recent functional MRI study, patients with disturbed sleep pattern exhibited decreased functional connectivity between the thalamus and some frontoparietal areas compared to those with normal sleep pattern [7]. Besides sleep disorders, several factors frequently observed in MS may precipitate this problem. These mainly include bladder dysfunction, with nocturia being the major contributor to middle and terminal insomnia [1]; and lower limb dyesthesias, which result from MS-related pathological changes in central sensory pathways and can affect up to 86% of patients [1]. It is also of great importance to consider the interaction between sleep and each of fatigue and mood [8]. Particularly, MS patients with poor sleep quality were found to have higher fatigue and depression scores [9]. Moreover, compared to patients without anxiety, those with anxiety were about two times more prone to experience sleep troubles [6]. In addition to these comorbidities, and despite the little available evidence, some disease modifying treatments (i.e. interferon-beta) and symptomatic drugs may affect sleep quality. Conversely, other treatments, such as natalizumab, may ameliorate sleep [10]. The paucity of studies with regards to this topic warrants further research. In conclusion, the available data hint toward a relatively high prevalence of sleep disturbances in MS patients. Admitting the drastic impact of sleep disturbance on physical and mental well-being [6], a systematic screening for sleep disorders in daily clinical practice should be implemented by adapting short quantitative assessment tools such as Epworth Sleepiness Scale [1]. This would allow a proper referral of concerned patients to sleep specialists for further investigations (e.g. polysomnography). Considering the frequent occurrence of comorbidities and their relationship with sleep quality, it would be of value to evaluate and treat fatigue (e.g. using the Modified Fatigue Impact Scale), mood disorders (e.g. by means of Hospital Anxiety and Depression Scale) and neuropathic pain (e.g. via the Neuropathic Pain Inventory), which may aggravate patients’ sleep problems [1]. Finally, sleep disorders merit to be addressed in future works for a better understanding of these pathologies and their relationships with MS comorbidities, in order to optimize therapeutic strategies and improve patients’ quality of life.

Declaration of Interest

This work did not receive any specific grant. MAC declares no conflict of interest. SSA declares having received travel grants or compensation from Genzyme, Biogen, Novartis and Roche.

References


